Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding
Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders, and in the majority of patients persists into adulthood. There is a lack of data regarding the risks of ADHD medication during pregnancy and breastfeeding. While some women may be ab...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2023-03-01
|
| Series: | European Psychiatry |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823004339/type/journal_article |
| _version_ | 1797617080233623552 |
|---|---|
| author | A. S. Vieira H. Santos I. Valada |
| author_facet | A. S. Vieira H. Santos I. Valada |
| author_sort | A. S. Vieira |
| collection | DOAJ |
| description |
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders, and in the majority of patients persists into adulthood. There is a lack of data regarding the risks of ADHD medication during pregnancy and breastfeeding. While some women may be able to discontinue without adverse effects, others may experience significant functional impairment. Due to the rising number of ADHD medication prescribed to women at child-bearing age, it is important to determine which medications can be considered relatively safe in pregnancy and lactation.
Objectives
We aim to review recent evidence on the risks of stimulant and non-stimulant treatment in pregnancy and lactation.
Methods
Literature review on the topic through PubMed and Google Scholar using the search terms: “ADHD”, “ADD” , “Pregnancy”, “Lactation OR breastfeeding”, “Stimulants”, “Methylphenidate OR Amphetamine OR lisdexamfetamine OR atomoxetine OR modafinil”. Only original research papers written in English were included.
Results
We identified twelve studies investigating the use of ADHD medication in pregnancy and four studies regarding lactation. Most of the studies did not find an elevated risk for congenital malformations by treatment with methylphenidate or medical amphetamines during pregnancy. A report suggested a moderate risk for congenital defects in infants exposed to modafinil in utero. The teratogenic effects of atomoxetine and guanfacine have not been investigated. Regarding lactation, only case reports and case series were found. Methylphenidate seems to be safe, with little transfer into breast milk and no reported adverse effects for the baby. Amphetamines transfer into breast milk and reach relatively high concentrations, and although the overall risk for intoxication seems to be low it cannot be fully excluded.
Conclusions
Prescription of ADHD medication to pregnant and lactating women should be considered after an individual risk-benefit estimation. In severe cases, when medication cannot be discontinued, the overall risk for adverse outcomes seem to be relatively low. More higher quality studies are needed on the topic.
Disclosure of Interest
None Declared |
| first_indexed | 2024-03-11T07:50:43Z |
| format | Article |
| id | doaj.art-a094c52fb9fa4e598e876bf2b5494545 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:50:43Z |
| publishDate | 2023-03-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-a094c52fb9fa4e598e876bf2b54945452023-11-17T05:06:53ZengCambridge University PressEuropean Psychiatry0924-93381778-35852023-03-0166S180S18010.1192/j.eurpsy.2023.433Treating Attention-deficit/hyperactivity disorder During Pregnancy and BreastfeedingA. S. Vieira0H. Santos1I. Valada2Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, PortugalCentro Hospitalar Psiquiátrico de Lisboa, Lisboa, PortugalCentro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders, and in the majority of patients persists into adulthood. There is a lack of data regarding the risks of ADHD medication during pregnancy and breastfeeding. While some women may be able to discontinue without adverse effects, others may experience significant functional impairment. Due to the rising number of ADHD medication prescribed to women at child-bearing age, it is important to determine which medications can be considered relatively safe in pregnancy and lactation. Objectives We aim to review recent evidence on the risks of stimulant and non-stimulant treatment in pregnancy and lactation. Methods Literature review on the topic through PubMed and Google Scholar using the search terms: “ADHD”, “ADD” , “Pregnancy”, “Lactation OR breastfeeding”, “Stimulants”, “Methylphenidate OR Amphetamine OR lisdexamfetamine OR atomoxetine OR modafinil”. Only original research papers written in English were included. Results We identified twelve studies investigating the use of ADHD medication in pregnancy and four studies regarding lactation. Most of the studies did not find an elevated risk for congenital malformations by treatment with methylphenidate or medical amphetamines during pregnancy. A report suggested a moderate risk for congenital defects in infants exposed to modafinil in utero. The teratogenic effects of atomoxetine and guanfacine have not been investigated. Regarding lactation, only case reports and case series were found. Methylphenidate seems to be safe, with little transfer into breast milk and no reported adverse effects for the baby. Amphetamines transfer into breast milk and reach relatively high concentrations, and although the overall risk for intoxication seems to be low it cannot be fully excluded. Conclusions Prescription of ADHD medication to pregnant and lactating women should be considered after an individual risk-benefit estimation. In severe cases, when medication cannot be discontinued, the overall risk for adverse outcomes seem to be relatively low. More higher quality studies are needed on the topic. Disclosure of Interest None Declaredhttps://www.cambridge.org/core/product/identifier/S0924933823004339/type/journal_article |
| spellingShingle | A. S. Vieira H. Santos I. Valada Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding European Psychiatry |
| title | Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding |
| title_full | Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding |
| title_fullStr | Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding |
| title_full_unstemmed | Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding |
| title_short | Treating Attention-deficit/hyperactivity disorder During Pregnancy and Breastfeeding |
| title_sort | treating attention deficit hyperactivity disorder during pregnancy and breastfeeding |
| url | https://www.cambridge.org/core/product/identifier/S0924933823004339/type/journal_article |
| work_keys_str_mv | AT asvieira treatingattentiondeficithyperactivitydisorderduringpregnancyandbreastfeeding AT hsantos treatingattentiondeficithyperactivitydisorderduringpregnancyandbreastfeeding AT ivalada treatingattentiondeficithyperactivitydisorderduringpregnancyandbreastfeeding |